BB Healthcare Trust PLC Issue of Equity (7862F)

TIDMBBH

RNS Number : 7862F

BB Healthcare Trust PLC

18 November 2020

 
 18 November 2020 
 
 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, 
  TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, 
  JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) 
  OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA, 
  CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF 
  THE EEA (OTHER THAN THE UNITED KINGDOM OR TO PROFESSIONAL INVESTORS 
  IN IRELAND) 
 
                           BB Healthcare Trust plc 
 
                           Issue of Ordinary Shares 
 
 BB Healthcare Trust plc (the "Company") announces that it has today 
  issued 240,000 of its ordinary shares of one penny each ("Ordinary 
  Shares") pursuant to its block listing facility. The Ordinary Shares 
  will be issued at a price of 175.40 pence per Ordinary Share, a premium 
  to the prevailing net asset value ("cum income") per Ordinary Share. 
 
 Following the issue of Ordinary Shares, the Company's issued share 
  capital will comprise (486,194,689) Ordinary Shares and this is the 
  total number of Ordinary Shares with voting rights in the Company. 
  This figure (486,194,689) may be used by shareholders as the denominator 
  for the calculations by which they will determine if they are required 
  to notify their interest in, or a change to, their interest in the 
  Company under the Financial Conduct Authority's Disclosure Guidance 
  and Transparency Rules. 
 
 The Company's LEI is: 213800HQ3J3H9YF2UI82 
 
 For further information please contact: 
 
  Peel Hunt LLP 
  Liz Yong, Tom Pocock (Investment Banking) 
  Alex Howe, Ed Welsby (Sales) 
  Telephone: [phone] 
 
  J.P. Morgan Cazenove 
  James Bouverat (Sales) 
  Telephone: [phone] 
 
  Bellevue Asset Management (UK) Ltd. 
  Mark Ghahramani 
  Telephone: [phone] 
 
 
 Disclaimer 
 
 This announcement does not constitute a prospectus relating to the 
  Company and does not constitute, or form part of, any offer or invitation 
  to sell or issue, or any solicitation of any offer to purchase or 
  subscribe for, any shares in the Company in any jurisdiction nor shall 
  it, or any part of it, or the fact of its distribution, form the basis 
  of, or be relied on in connection with or act as any inducement to 
  enter into, any contract therefore. 
 
 Peel Hunt LLP ("Peel Hunt") and J.P. Morgan Cazenove, which are authorised 
  and regulated by the Financial Conduct Authority, are acting for the 
  Company only in connection with the matters described in this announcement 
  and are not acting for or advising any other person, or treating any 
  other person as their client, in relation thereto and will not be 
  responsible for providing the regulatory protection afforded to clients 
  of Peel Hunt and J.P. Morgan Cazenove or advice to any other person 
  in relation to the matters contained herein. 
 
 The shares of the Company have not been and will not be registered 
  under the US Securities Act of 1933, and may not be offered or sold 
  in the United States absent registration or an applicable exemption 
  from the registration requirements. Moreover, the shares of the Company 
  have not been, nor will they be, registered under the applicable securities 
  laws of Australia, Canada, the Republic of South Africa, Japan or 
  any member state of the EEA (other than the United Kingdom). Further, 
  the Company will not be registered under the US Investment Company 
  Act of 1940, as amended. Subject to certain exceptions, the shares 
  of the Company may not be offered or sold in the United States, Australia, 
  Canada, the Republic of South Africa, Japan or any member state of 
  the EEA (other than the United Kingdom or to professional investors 
  in Ireland) or to, or for the account or benefit of, any national, 
  resident or citizen of the United States, Australia, Canada, the Republic 
  of South Africa, Japan or any member state of the EEA (other than 
  the United Kingdom or to professional investors in Ireland). The share 
  issuance programme, and the distribution of this announcement, in 
  other jurisdictions may be restricted by law and the persons into 
  whose possession this announcement comes should inform themselves 
  about, and observe, any such restrictions. 
 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFSRLVLTLII

(END) Dow Jones Newswires

November 18, 2020 11:44 ET (16:44 GMT)